Evidence of novel oral anticoagulants (NOAC)

Research output: Contribution to journalArticle

Abstract

Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF). Phase III trials have compared each of these agents to warfarin. Dabigatran was more efficacious than warfarin in reducing the risk of stroke when given at a dose of 150?mg BID to patients with NVAF. Rivaroxaban 20?mg QD was superior to warfarin in on-treatment analysis. Apixaban 5?mg BID was also found to be superior to warfarin in reducing stroke in NVAF patients. Of note, the rate of hemorrhagic stroke was much smaller in the patients treated with NOAC than those with warfarin. NOAC offer a good therapeutic option for prevention of stroke in NVAF patients.

Original languageEnglish
Pages (from-to)992-993
Number of pages2
JournalClinical Neurology
Volume53
Issue number11
DOIs
Publication statusPublished - Dec 1 2013

Fingerprint

Warfarin
Anticoagulants
Stroke
Atrial Fibrillation
Antithrombins
Therapeutics
apixaban
Dabigatran
Rivaroxaban

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Evidence of novel oral anticoagulants (NOAC). / Kitazono, Takanari.

In: Clinical Neurology, Vol. 53, No. 11, 01.12.2013, p. 992-993.

Research output: Contribution to journalArticle

@article{237b955e62f047e4846bb71db95f20ab,
title = "Evidence of novel oral anticoagulants (NOAC)",
abstract = "Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF). Phase III trials have compared each of these agents to warfarin. Dabigatran was more efficacious than warfarin in reducing the risk of stroke when given at a dose of 150?mg BID to patients with NVAF. Rivaroxaban 20?mg QD was superior to warfarin in on-treatment analysis. Apixaban 5?mg BID was also found to be superior to warfarin in reducing stroke in NVAF patients. Of note, the rate of hemorrhagic stroke was much smaller in the patients treated with NOAC than those with warfarin. NOAC offer a good therapeutic option for prevention of stroke in NVAF patients.",
author = "Takanari Kitazono",
year = "2013",
month = "12",
day = "1",
doi = "10.5692/clinicalneurol.53.992",
language = "English",
volume = "53",
pages = "992--993",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "11",

}

TY - JOUR

T1 - Evidence of novel oral anticoagulants (NOAC)

AU - Kitazono, Takanari

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF). Phase III trials have compared each of these agents to warfarin. Dabigatran was more efficacious than warfarin in reducing the risk of stroke when given at a dose of 150?mg BID to patients with NVAF. Rivaroxaban 20?mg QD was superior to warfarin in on-treatment analysis. Apixaban 5?mg BID was also found to be superior to warfarin in reducing stroke in NVAF patients. Of note, the rate of hemorrhagic stroke was much smaller in the patients treated with NOAC than those with warfarin. NOAC offer a good therapeutic option for prevention of stroke in NVAF patients.

AB - Novel oral anticoagulants (NOAC) such as the direct thrombin inhibitor, dabigatran, and oral factor Xa inhibitors, rivaroxaban and apixaban, have recently approved for prevention of stroke in nonvalvular atrial fibrillation (NVAF). Phase III trials have compared each of these agents to warfarin. Dabigatran was more efficacious than warfarin in reducing the risk of stroke when given at a dose of 150?mg BID to patients with NVAF. Rivaroxaban 20?mg QD was superior to warfarin in on-treatment analysis. Apixaban 5?mg BID was also found to be superior to warfarin in reducing stroke in NVAF patients. Of note, the rate of hemorrhagic stroke was much smaller in the patients treated with NOAC than those with warfarin. NOAC offer a good therapeutic option for prevention of stroke in NVAF patients.

UR - http://www.scopus.com/inward/record.url?scp=84891789246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891789246&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.53.992

DO - 10.5692/clinicalneurol.53.992

M3 - Article

VL - 53

SP - 992

EP - 993

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 11

ER -